Venus Concept

Venus Concept FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Venus Concept (VERO) as of Oct 23, 2026 is 23.81 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 34.83 % — a change of -31.65% (lower).

FCF Conversion

23.81 %

YoY

-31.65%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Venus Concept is 2024 23.81 % . FCF Conversion Rate (FCF/EBITDA) of Venus Concept was 2023 34.83 % . It decreases by -31.65% lower compared to the previous year.

The Venus Concept FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
109.21 USD
Jan 1, 2018
103.41 USD
Jan 1, 2019
96.27 USD
Jan 1, 2020
34.95 USD
Jan 1, 2021
91.61 USD
Jan 1, 2022
62.51 USD
Jan 1, 2023
34.83 USD
Jan 1, 2024
23.81 USD
The Venus Concept FCF Conversion history
YEARFCF ConversionYoY
23.81 %-31.65%
34.83 %-44.28%
62.51 %-31.77%
91.61 %+162.15%
34.95 %-63.70%
96.27 %-6.90%
103.41 %-5.31%
109.21 %+37.61%
79.36 %-25.82%
106.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Venus Concept Stock analysis

What does Venus Concept do? Venus Concept, Inc. generates revenue through its portfolio of medical aesthetic and hair restoration technologies, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Freeze Plus, Venus Heal, Venus Skin, and Venus Bliss. The company sells these products to clinics and medical practices globally, operating in over 60 countries and 29 direct markets. Its hair restoration division features NeoGraft, an automated system for follicular unit extraction (FUE) procedures. Venus Viva combines NanoFractional Radio Frequency (RF) and SmartScan technology for facial, neck, and body treatments, while Venus Fiore targets vaginal health restoration with three specialized applicators. The company’s revenue streams include direct sales of devices and related practice enhancement services. Products like Venus Legacy and Venus Freeze Plus are marketed for non-invasive aesthetic procedures, while NeoGraft serves the hair restoration segment. Venus Fiore focuses on internal vaginal health, labia tightening, and mons pubis reduction, addressing niche medical needs. All offerings are distributed through the company’s global network, leveraging its presence in 29 direct markets. Venus Concept’s business model centers on selling minimally invasive and non-invasive medical aesthetic technologies to healthcare providers. The company’s product range spans multiple applications, from facial rejuvenation to hair restoration and intimate health. By maintaining a diverse portfolio under its branded products, Venus Concept ensures steady demand across various medical specialties and geographic regions. Venus Concept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Venus Concept stock

FCF Conversion Rate (FCF/EBITDA) of Venus Concept is 23.81 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Venus Concept changed from 34.83 % to 23.81 %, representing a -31.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Venus Concept since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Venus Concept with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Venus Concept

All Key Metrics — Venus Concept